Key takeaways
- The WHI signal came from a synthetic progestin; the oestrogen-only arm of the same trial did not reproduce it.
- Progestins engage androgenic and glucocorticoid receptors as well as the progesterone receptor, which is the proposed reason breast tissue responds differently.
- The progestogen exists to protect the endometrium, so women without a uterus generally do not need one at all.
Twenty-plus years after the headline, most women considering hormone therapy still carry one sentence in their head: HRT causes breast cancer. The trial that produced it tested one specific combination — a conjugated equine oestrogen with a synthetic progestin — in a population whose average age was well past the menopausal transition. The progestogen component in that combination is not the molecule modern therapy uses, and that distinction is where most of the argument now lives.
What WHI actually tested
The Women's Health Initiative reported an increase in breast cancer in the combined hormone arm relative to placebo (Rossouw et al., JAMA 2002). It was reported everywhere, prescribing collapsed, and a generation of women were left with the impression that the category as a whole was dangerous.
Two details are load-bearing. The regimen was conjugated equine oestrogens plus medroxyprogesterone acetate — MPA, a synthetic progestin. And the oestrogen-only arm, given to women who had had a hysterectomy and therefore needed no progestogen, did not show the same breast signal. Whatever was driving the finding, the arm without the progestin did not produce it. That is the observation the subsequent twenty years of work has been trying to explain.
Progestin and progesterone are not synonyms
The vocabulary here is genuinely confusing, and the confusion is not accidental — the words were used interchangeably in clinical writing for decades.
- Progesterone is the human hormone, produced by the corpus luteum and, in pregnancy, the placenta. Micronised progesterone prescribed today is structurally identical to it.
- A progestin is a synthetic compound designed to activate the progesterone receptor. It was engineered for oral stability and contraceptive potency, not for structural fidelity.
Progestins such as MPA, norethindrone and levonorgestrel do activate the progesterone receptor. They also bind other steroid receptors — androgenic, glucocorticoid, mineralocorticoid — to varying degrees depending on the molecule, because the steroid receptor family shares enough architecture that a compound shaped for one will often engage another. That off-target activity is not a rounding error. It is the reason different progestogens produce different clinical profiles despite nominally doing the same job.
Why the breast responds differently
Breast epithelium is hormonally responsive tissue whose proliferation rate is set by the signalling it receives. The proposed mechanism for the difference runs roughly as follows.
MPA carries substantial androgenic and glucocorticoid activity alongside progesterone receptor activation. Bioidentical progesterone is comparatively selective. In laboratory and animal work, the two produce measurably different effects on breast tissue — different proliferative signalling, different gene expression downstream — and in some contexts progesterone appears anti-proliferative rather than proliferative. The clinical corollary is that a combination containing MPA and a combination containing micronised progesterone should not be assumed to carry the same breast risk simply because both are described as "oestrogen plus a progestogen."
Worth being precise about the limits of that reasoning: mechanistic plausibility is a reason to look, not a result. The human evidence is what determines whether the mechanism translates.
What the human data shows, and what it does not
The largest body of relevant evidence comes from observational cohorts rather than randomised trials. The French E3N cohort, which followed a large number of women using a range of hormone regimens, found no significant breast cancer increase among users of oestrogen combined with bioidentical progesterone, while progestin-containing regimens in the same cohort did show elevated risk (Fournier et al., Breast Cancer Res Treat 2008). Systematic review of micronised progesterone points the same direction (Stute et al., Climacteric 2018).
Now the honest caveats, because they matter to the decision. Observational cohorts cannot fully exclude that women prescribed one regimen differed from women prescribed another in ways that also affect risk. The reassurance is strongest for shorter durations of use and becomes less settled the longer therapy continues, simply because fewer women have been followed that far. And "no significant increase detected" is not the same statement as "no risk" — it means that if there is an effect, this evidence was not powered to see it.
What can be said with reasonable confidence: the specific signal that caused the panic came from a regimen containing a synthetic progestin, and the evidence available for micronised progesterone looks meaningfully more favourable. That is a real distinction and it is not marketing. It is also not a guarantee, and anyone presenting it as one has overreached.
Why a progestogen is prescribed at all
This is the question that reframes the whole decision, and it is frequently skipped. Progesterone in menopausal hormone therapy is not there to make you feel better. It is there to protect the endometrium.
Unopposed oestrogen drives proliferation of the uterine lining, and sustained proliferation raises the risk of endometrial hyperplasia and cancer. A progestogen opposes that. It follows directly that a woman who has had a hysterectomy does not need one — she takes oestrogen alone, and the trial arm that most closely resembles her situation is the one that did not show the breast signal. That single fact changes the calculation for a substantial number of women who have been avoiding therapy on the strength of a headline that did not describe their regimen.
For women with a uterus, the progestogen is not optional and the question is only which one, at what dose, and by what route.
How this plays out in practice
Modern prescribing has largely converged on a few positions:
- Bioidentical micronised progesterone is generally preferred when a progestogen is needed for endometrial protection
- Synthetic progestins remain in wide use in contraception, where the requirements are different, and are less commonly chosen for menopausal therapy
- Oral micronised progesterone is usually taken at night, because it is metabolised in part to allopregnanolone, which acts on GABA receptors and is sedating — an inconvenience by day and often a benefit at bedtime. The GABA mechanism explains why sleep frequently improves as a side effect
- For women without a uterus, oestrogen alone is appropriate
Route and timing of the oestrogen component matter too, and are a separate conversation from the progestogen — transdermal versus oral changes the thrombotic picture rather than the breast picture. The honest account of side effects covers what the first few months usually feel like, and timing of initiation covers the age question, which independently affects the risk-benefit balance.
Making the decision
A reasonable way through, in order. Establish whether you need a progestogen at all — that is decided by whether you have a uterus, not by preference. Establish your own baseline risk, which is driven by family history, breast density, prior biopsies and personal history far more than by anything a prescription adds or subtracts. Then weigh what therapy is for: symptom burden severe enough to affect function, bone protection, and the timing of initiation relative to menopause.
What should not drive the decision is a twenty-year-old headline about a different molecule, and neither should the opposite error — treating "bioidentical" as a word that removes the need for surveillance. Mammographic screening continues on schedule regardless of regimen, and any new breast change is evaluated the same way it would be in a woman on no therapy at all.
The clinical pearl: the progestin-progesterone distinction is one of the most consequential nuances in menopausal hormone therapy, and most women weighing the decision have never had it explained. Many are declining a therapy that would help them on the basis of a finding that came from a regimen they would not be prescribed.
Bottom line
The breast cancer signal that shaped a generation of prescribing came from a combination containing a synthetic progestin, not from bioidentical progesterone, and the oestrogen-only arm of the same trial did not reproduce it. Subsequent observational evidence on micronised progesterone looks meaningfully more favourable, with the caveats that it is observational and thinner at longer durations. Progesterone is prescribed to protect the endometrium, so women without a uterus generally do not need it at all. None of this makes hormone therapy risk-free or right for everyone — it makes the decision one worth having properly, with your own risk profile in front of you rather than a headline.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
